96516-32-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(2-chloro-3-fluorophenyl)Methanol is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a valuable component in the creation of new drugs, potentially leading to advancements in medicinal treatments.
Used in Agrochemical Production:
(2-chloro-3-fluorophenyl)Methanol also finds application in the production of agrochemicals, where it serves as an intermediate in the synthesis of various agricultural products, contributing to the development of more effective and targeted crop protection agents.
Used in Fine Chemicals Synthesis:
(2-chloro-3-fluorophenyl)Methanol is employed in the synthesis of fine chemicals, which are high-purity, specialty chemicals used in various industries, including the fragrance, flavor, and cosmetics industries.
Used in Dye Production:
Additionally, (2-chloro-3-fluorophenyl)Methanol is used as an intermediate in the production of dyes, where its specific structural features contribute to the development of new dye compounds with unique properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2-chloro-3-fluorophenyl)Methanol is being studied for its potential biological activities and pharmacological effects, which could lead to the discovery of new therapeutic agents and contribute to the advancement of medical science.

Upstream product

• 102940-86-3 3-chloro-3-fluorobenzoic acid 

Downstream Products

• 96516-31-3 2-chloro-3-fluoro-benzaldehyde 
• 1292850-11-3 [5-chloro-2-(2,2-dimethylpropylamino)phenyl]-(2-chloro-3-fluorophenyl)methanol 
• 1292850-10-2 N-{4-chloro-2-[(2-chloro-3-fluorophenyl)hydroxymethyl]-phenyl}-2,2-dimethylpropionamide 
• 874285-19-5 1-(bromomethyl)-2-chloro-3-fluorobenzene 

Relevant academic research and scientific papers

Discovery of Highly Potent Liver X Receptor β Agonists

Introducing a uniquely substituted phenyl sulfone into a series of biphenyl imidazole liver X receptor (LXR) agonists afforded a dramatic potency improvement for induction of ATP binding cassette transporters, ABCA1 and ABCG1, in human whole blood. The ag

Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors

To obtain small and efficient squalene synthase inhibitors, a flexible 2-aminobenzhydrol open form structure was designed and showed potent inhibitory activity comparable to 4,1-benzoxazepin compounds. Further chemical modification led to the discovery of a novel template with a strong squalene synthase inhibitory activity, and its basic structure-activity relationship was revealed. The X-ray crystallographic data of compound 12 bound to the active site of squalene synthase provided an important insight into the binding mode of this alternative template that formed 11-membered ring conformations with an intramolecular hydrogen bond.

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto - enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited-marked antiretroviral activity. Here, we show the synthesis and the detailed structure - activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3,3- dimethylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nMin the strand transfer assay and an ED50 of 0.6 nMin the antiviral assay, and 6-(3-chloro-2-fluorobenzyl) -1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid 49, which had an IC50 of 7.2 nMand an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrasecatalyzed strand transfer processes than 3′-processing reactions, as is the case with the keto - enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.